PT - JOURNAL ARTICLE AU - Sharma, Mrinank AU - Mindermann, Sören AU - Rogers-Smith, Charlie AU - Leech, Gavin AU - Snodin, Benedict AU - Ahuja, Janvi AU - Sandbrink, Jonas B. AU - Monrad, Joshua Teperowski AU - Altman, George AU - Dhaliwal, Gurpreet AU - Finnveden, Lukas AU - Norman, Alexander John AU - Oehm, Sebastian B. AU - Sandkühler, Julia Fabienne AU - Mellan, Thomas AU - Kulveit, Jan AU - Chindelevitch, Leonid AU - Flaxman, Seth AU - Gal, Yarin AU - Mishra, Swapnil AU - Brauner, Jan Markus AU - Bhatt, Samir TI - Understanding the effectiveness of government interventions in Europe’s second wave of COVID-19 AID - 10.1101/2021.03.25.21254330 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.25.21254330 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254330.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254330.full AB - As European governments face resurging waves of COVID-19, non-pharmaceutical interventions (NPIs) continue to be the primary tool for infection control. However, updated estimates of their relative effectiveness have been absent for Europe’s second wave, largely due to a lack of collated data that considers the increased subnational variation and diversity of NPIs. We collect the largest dataset of NPI implementation dates in Europe, spanning 114 subnational areas in 7 countries, with a systematic categorisation of interventions tailored to the second wave. Using a hierarchical Bayesian transmission model, we estimate the effectiveness of 17 NPIs from local case and death data. We manually validate the data, address limitations in modelling from previous studies, and extensively test the robustness of our estimates. The combined effect of all NPIs was smaller relative to estimates from the first half of 2020, indicating the strong influence of safety measures and individual protective behaviours--such as distancing--that persisted after the first wave. Closing specific businesses was highly effective. Gathering restrictions were highly effective but only for the strictest limits. We find smaller effects for closing educational institutions compared to the first wave, suggesting that safer operation of schools was possible with a set of stringent safety measures including testing and tracing, preventing mixing, and smaller classes. These results underscore that effectiveness estimates from the early stage of an epidemic are measured relative to pre-pandemic behaviour. Updated estimates are required to inform policy in an ongoing pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM. Sharma was supported by the EPSRC Centre for Doctoral Training in Autonomous Intelligent Machines and Systems (EP/S024050/1) and a grant from the EA Funds programme. S. Mindermann's funding for graduate studies was from Oxford University and DeepMind. C. Rogers-Smith was supported by a grant from Open Philanthropy. A.J. Norman was supported by the U.K. BBSRC and Open Philanthropy. J Ahuja was supported by Open Philanthropy. J. T. Monrad was supported by the Augustinus Foundation, the Knud Hojgaard Foundation, the William Demant Foundation, the Kai Lange and Gunhild Kai Lange Foundation, and the Aage and Johanne Louis-Hansen Foundation. G.Leech was supported by the UKRI Centre for Doctoral Training in Interactive Artificial Intelligence (EP/S022937/1). S.B. Oehm was supported by the Boehringer Ingelheim Fonds. L.Chindelevitch and S.Bhatt acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (MR/R015600/1), jointly funded by the U.K. Medical Research Council (MRC) and the U.K. Foreign, Commonwealth and Development Office (FCDO), under the MRC/FCDO Concordat agreement; are part of the EDCTP2 program supported by the European Union; and acknowledge funding by Community Jameel. S. Flaxman acknowledges the EPSRC (EP/V002910/1) and the Imperial College COVID-19 Research Fund. J.M. Brauner was supported by the EPSRC Centre for Doctoral Training in Autonomous Intelligent Machines and Systems (EP/S024050/1) and by Cancer Research UK. S. Bhatt acknowledges The UK Research and Innovation (MR/V038109/1), the Academy of Medical Sciences Springboard Award (SBF004/1080), The MRC (MR/R015600/1), The BMGF (OPP1197730), Imperial College Healthcare NHS Trust- BRC Funding (RDA02), The Novo Nordisk Young Investigator Award (NNF20OC0059309) and The NIHR Health Protection Research Unit in Modelling Methodology. S. Bhatt thanks Microsoft AI for Health and Amazon AWS for computational credits. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approval required for research on public, fully anonymised data, as per the Central University Research Ethics Committee (CUREC) of the University of Oxford. https://researchsupport.admin.ox.ac.uk/governance/ethics/applyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request